Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04850612
Other study ID # CA_2020-21-303
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date April 30, 2021
Est. completion date December 1, 2023

Study information

Verified date May 2023
Source University Hospital Plymouth NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is aimed at improving reporting in Chronic Subdural Haematoma (CSDH) research studies, through development of a standardised Core Outcome Set (COS), a unified CSDH Definition and set of Data Elements (DE) for reporting. The study design includes a Delphi survey process from two main stakeholder groups: Health-Care Professionals or Researchers (HCPR) and Patients or carers. HCPR, patients and carers will all be invited to complete the survey on the COS, only the HCPR survey will include questions on definition and DE. Results of the Delphi Survey will be discussed at a final consensus meeting before results are confirmed and published.


Description:

Chronic subdural haematoma (CSDH) is a collection of blood and fluid surrounded by membranes that accumulates on the brain surface over weeks to months. It predominately affects older people and often has a delayed association with a preceding head trauma. There has been significant growth in the number of CSDH publications in recent years mirroring progress in potential management options but there is wide variation in how and when patient outcome is measured amongst studies. Much could be gained by agreeing a minimum set of standardized outcomes that should be measured and reported in all CSDH studies, known as a Core Outcome Set (COS). The overall study design includes a Delphi survey process.This is a process whereby all outcomes and data elements from the CSDH literature and expert opinion are presented to a large group of patients, carers and HCPR via a survey. Each survey participant has the opportunity to rank the elements and outcomes in levels of importance to them, and the survey is then repeated including presentation of the results from the first round, in order to attempt to gain agreement between participants on what is important. All elements are then reviewed at a final "consensus" meeting


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 150
Est. completion date December 1, 2023
Est. primary completion date September 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All invited participants who provide consent to take part in 2 rounds of survey

Study Design


Intervention

Other:
Survey
Delphi Survey on core outcomes, CSDH definition and data elements

Locations

Country Name City State
United Kingdom University Hospitals Plymouth NHS Trust Plymouth

Sponsors (5)

Lead Sponsor Collaborator
University Hospital Plymouth NHS Trust Barts & The London NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Erasmus Medical Center, Université de Sherbrooke

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary CSDH Core Outcome Set (COS) Definition of a Core Outcome Set (COS) for reporting in all future CSDH studies through a Delphi survey process including all relevant stakeholders. 3 months
Secondary CSDH Definition and Data Elements Identify a unified CSDH definition and data elements (DE) for reporting in future CSDH studies, through a Delphi survey process including healthcare profession and research (HCPR) stakeholders. 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06347796 - Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study N/A
Recruiting NCT04065113 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma N/A
Recruiting NCT02938468 - Mgt of Chronic Subdural Hematoma Using Dexamethasone Phase 2/Phase 3
Completed NCT03307395 - Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma N/A
Terminated NCT04502745 - A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation N/A
Terminated NCT03353259 - Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Phase 2/Phase 3
Recruiting NCT02568124 - Tranexamic Acid in Chronic Subdural Hematomas Phase 2/Phase 3
Completed NCT02282228 - Detecting Chronic Subdural Hematoma With Microwave Technology N/A
Recruiting NCT05143216 - High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
Active, not recruiting NCT04816591 - Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA N/A
Recruiting NCT06401772 - The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma N/A
Completed NCT06134206 - Burr Hole Ultrasound Study N/A
Recruiting NCT03666949 - General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma N/A
Recruiting NCT03280212 - Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma Phase 3
Completed NCT03447327 - Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma N/A
Recruiting NCT05374681 - Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization N/A
Recruiting NCT05267184 - Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma N/A
Not yet recruiting NCT05900557 - Neurologic Deficits and Recovery in Chronic Subdural Hematoma N/A
Completed NCT02757235 - The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma N/A
Terminated NCT02111785 - Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Phase 2/Phase 3